Table 3.
Proportion of days using sedative agents
| Benzodiazepines | ||||
| Overall | 17,627/24925 (71%) | 12,955/23520 (55%) | − 0.156 (− 0.16 to − 0.152) | < 0.001 |
| Europe | 7178/11773 (61%) | 4939/10468 (47%) | − 0.138 (− 0.145 to − 0.131) | < 0.001 |
| US/Canada | 1803/2439 (74%) | 372/1030 (36%) | − 0.378 (− 0.397 to − 0.359) | < 0.001 |
| Asia | 2725/3401 (80%) | 2093/4507 (46%) | − 0.337 (− 0.346 to − 0.328) | < 0.001 |
| Africa | 267/281 (95%) | 448/500 (90%) | − 0.054 (− 0.069 to − 0.039) | < 0.001 |
| Australia/New Zealand | 887/2016 (44%) | 122/577 (21%) | − 0.229 (− 0.255 to − 0.203) | < 0.001 |
| Latin America | 4767/5015 (95%) | 4981/6438 (77%) | − 0.177 (− 0.183 to − 0.171) | < 0.001 |
| Propofol | ||||
| Overall | 9526/24925 (38%) | 9728/23520 (41%) | 0.031 (0.027 to 0.035) | < 0.001 |
| Europe | 6012/11773 (51%) | 6095/10468 (58%) | 0.072 (0.064 to 0.08) | < 0.001 |
| US/Canada | 829/2439 (34%) | 672/1030 (65%) | 0.313 (0.294 to 0.332) | < 0.001 |
| Asia | 876/3401 (26%) | 1380/4507 (31%) | 0.049 (0.039 to 0.059) | < 0.001 |
| Africa | 15/281 (5%) | 34/500 (7%) | 0.015 (0.002 to 0.028) | 0.023 |
| Australia/New Zealand | 1545/2016 (77%) | 496/577 (86%) | 0.093 (0.069 to 0.117) | < 0.001 |
| Latin America | 249/5015 (5%) | 1051/6438 (16%) | 0.114 (0.108 to 0.12) | < 0.001 |
| Dexmedetomidine | ||||
| Overall | 196/24925 (0.8%) | 2615/23520 (11%) | 0.103 (0.101 to 0.105) | < 0.001 |
| Europe | 24/11773 (0.2%) | 609/10468 (6%) | 0.056 (0.053 to 0.059) | < 0.001 |
| US/Canada | 5/2439 (0.2%) | 84/1030 (8%) | 0.08 (0.068 to 0.092) | < 0.001 |
| Asia | 14/3401 (0.4%) | 1309/4507 (29%) | 0.286 (0.28 to 0.292) | < 0.001 |
| Africa | 0/281 (0%) | 0/500 (0%) | – | – |
| Australia/New Zealand | 32/2016 (1.6%) | 59/577 (10%) | 0.086 (0.07 to 0.102) | < 0.001 |
| Latin America | 121/5015 (2.4%) | 554/6438 (9%) | 0.062 (0.057 to 0.067) | < 0.001 |
Proportion of days using each sedative out of the total days when any sedation was received